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1. Introduction 
The core clinical features of Huntington’s Disease (HD) were outlined by George 
Huntington in 1872 (Huntington 1872). Like nowadays , in George Huntington’s time no 
cure for HD was yet available. However, genetic testing for HD that is now available can 
reliably predict the individuals at risk that will develop the disease. In such premanifest 
individuals slowing down the disease process may potentially delay the onset of disease 
symptoms. Therefore, there is an increasing need of finding the markers for the disease 
progression in premanifest HD individuals. 
A biomarker is defined as an attribute of the disease that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes or 
pharmacological response to a therapeutic intervention (Biomarkers definitions working 
group 2001). In adult HD mouse it has been demonstrated that stopping the expression of 
mutant Huntingtin may reverse the clinical and pathological phenotype (Yamamoto et al 
2000). However, treatment trials expected to modify disease progression remain confined to 
population of manifest HD patients until reliable markers of disease process progression can 
be found for the premanifest HD gene carriers. Clinical measures may be used as primary 
endpoints and we will first focus on them. In our opinion, a comprehensive neurological 
and physical examination of premanifest HD gene carriers represents a reliable way 
towards identification of potential clinical biomarkers.  
2. Clinical biomarkers for HD 
A broad consensus exists among clinicians that a clinical diagnosis of HD can be made with 
certainty only in the presence of specific motor disorders. Thus, fixing the onset of the motor 
disorder in this way is a more or less reproducible method to conduct age at onset surveys 
or genotype-phenotype correlation studies (Kremer 2002). The most complete technique of 
assessing the early signs and symptoms of HD is to follow up a cohort of at risk individuals 
for an extended period of time. The most instructive follow-up study continues to be the one 
of the Venezuelan HD kindred (Penney et al 1990). It was performed prior to identification 
of the gene; nevertheless its conclusions are still valid. It demonstrated that patients pass 
through a transitional state from the normal presymptomatic phase to the time at which the 
diagnosis can clearly be made on neurological examination. The study revealed that there 
www.intechopen.com
 
Huntington’s Disease — Core Concepts and Current Advances 
 
102 
was no single presenting sign or symptom in HD. In the earliest phases there was an 
insidious and slow deterioration of intellectual functions as well as mild personality change. 
The clear appearance of extrapyramidal signs such as chorea, hypokinesia, rigidity or 
dystonia indicates a phase on the disease progression, not the beginning of the disease. Prior 
to these signs however, most individuals will display minor motor abnormalities (Penney et 
al 1990). These minor abnormalities include general restlessness, abnormal eye movements, 
or impaired optokinetic nystagmus, hyperreflexia, impaired finger tapping or rapid 
alternating hand movements, and excessive and inappropriate movements of the fingers, 
hands, or toes during emotional stress as well as mild dysarthria. Minor abnormalities 
usually precede the obvious signs of extrapyramidal dysfunction by at least 3 years. Persons 
with a completely normal neurological examination have only a 3 per cent chance of being 
diagnosed as clinically manifest HD patients within the next 3 years (Penney et al 1990). A 
retrospective assessment of the affected individuals has revealed that minor involuntary 
movements are among the earliest symptoms experienced and that soon by those mental 
and emotional symptoms, including sadness, depression, irritability, and episodes of verbal 
and physical abuse may develop (Kirkwood et al 2001). Various research groups have 
revealed that so-called asymptomatic gene carriers statistically display subtle cognitive 
defects; such subtle cognitive deficits may precede motor abnormalities by years 
(Campodonico et al 1996, Lawrence et al 1998). However, it is important to realize that 
individuals with expanded repeats due to HD mutation may perform just as well or better 
than matched controls. Only when an individual is close to the estimated age of onset, as 
predicted by cytosine-adenine-guanine (CAG) repeat length (Brinkman et al 1997) that 
minor deficits in selected cognitive domain may become apparent (Campodonico et al 1996). 
2.1 Unified Huntington’s Disease rating scale  
Clinical biomarkers are standardised clinical tests and rating scales that measure progression 
of HD phenotype. In order to provide a comprehensive assessment of motor performance, 
cognitive functioning, behavioral and psychiatric problems and functional status of an 
individual the United Huntington’s Disease Rating Scale (UHDRS) was developed by the 
Huntington Study Group (Huntington Study group 1996). It enables a comprehensive, rapid, 
and efficient survey that is highly sensitive to disease progression over relatively short periods 
of time, such as 1 year. Using the UHDRS clinical score subtle motor abnormalities were found 
in premanifest HD subjects and were increasing with the proximity of the predicted time of 
clinical diagnosis (Biglan et al 2009). Although UHDRS is a standard assessment of disease 
progression it does not encompass every possible manifestation of HD. Special techniques 
have been developed to detect subtle premanifest clinical abnormalities that may lead to the 
development of new potential clinical biomarkers. HD progression may additionally be 
tracked by clinical techniques of oculomotor assessment (Klöppel et al 2008), tapping test 
(Andrich et al 2007), and gait analysis (Rao et al 2005).  
2.2 Cognitive impairment 
Subtle cognitive changes are present already in presymptomatic gene carriers (Kirkwood et 
al 2001, Craufurd & Snowden 2002); they become evident close to onset and early in the 
course of the disease and grow to be more severe as the disease evolves (Campodonico et al 
1996; Brandt & Butters 1986). Cognitive changes therefore have the potential to identify 
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premanifest HD gene carriers close to the onset of the disease. Asides to Clinical 
psychological tests encompassed in the UHDRS (Verbal fluency, Symbol digit and Stroop 
test) other neuropsychological test batteries may be used for the purpose. However, the 
natural history of HD-related cognitive impairment is still not completely understood. 
Executive tests, combined with neuroimaging techniques have provided new evidence of 
cognitive abnormalities in HD; abnormal connectivity between basal ganglia and cortical 
areas has been suggested (Montoya et al 2006). 
3. Positron emission tomography  
Prior to HD gene identification the transitional state in HD development was proven to be 
accompanied by changes in metabolic rates of glucose as seen on positron emission 
tomography (PET) (Grafton et al 1992). After identification of the HD gene Huntington’s 
disease Collaborative Research Group 1993) longitudinal follow up studies of identified 
presymptomatic gene carriers were started. Using serial 11C-SCH 23390 and 11C-raclopride 
PET striatal dopamine D1 and D2 receptor binding was followed in a group of HD gene 
carriers of which 4 were in transitional state (Andrews et al 1999). The affected subjects 
showed mean annual reductions of 5.0 and 3.0 per cent loss of striatal dopamine D1 an D2 
binding, respectively, while presymptomatic HD gene carriers showed mean annual 
reductions of 2.0 and 4.0 per cent, respectively. In mutation negative group no loss of 
dopamine binding was detected. The rate of loss of striatal dopamine D2 receptors 
correlated with CAG repeat length in presymptomatic HD gene carriers. Longitudinal 
studies have shown a mean annual decrease in dopamine D2 receptor binding of 5-6 per 
cent in HD patients and of around 4 per cent in premanifest HD gene carriers (Pavese et al 
2003) Microglial activation was observed in the striatum of both HD patients and 
presymptomatic HD gene carriers by reduced binding of 11C-raclopride (Pavese et al 2006). 
The correlation with probability of time of onset was also shown in presymptomatic HD. 
(Tai et al 2007). Two-stage PET scanning method was applied to a cohort of presymptomatic 
and symptomatic HD individuals; this technique enables better visualization of anatomic 
structures and might potentially serve as a useful biomarker in the future. (Tomasi et al 
2011). 
PET scanning therefore shows promise for early visualization and quantification of 
pathological abnormalities in HD and therefore may be helpful in finding new potential 
biomarkers. There are however a number of weaknesses which limit usefulness of this 
technique. The cost is high and availability limited, scanning is time-consuming, radioactive 
ligands are difficult to manipulate. PET scanning also is susceptible to neuroleptic abuse 
which is common in HD patients. 
4. Magnetic resonance imaging  
Volumetric magnetic resonance imaging (MRI) enables estimation of brain region volumes. 
T1 volumetric MRI is the standard MRI technique most often used also in HD; however, 
other standard MRI techniques may provide useful information as well.  
Longitudinal studies have shown significantly faster brain atrophy in early HD patients 
(Aylard et al 1997) and in presymptomatic gene carriers as far as 11 years from the predicted 
onset (Aylard et al 2004). Longitudinal assessment of striatal volumes thus seems to hold 
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capacity of providing potential biomarkers. The use of T1 weighted combined to diffusion–
weighted scans seem to provide good information about the nature, and topographic 
specificity of brain changes in pre–HD individuals (Stoffers et al 2010). Basal ganglia are 
parts of the brain that are most affected by atrophy in HD patients, however, atrophy of 
other parts of the brain also takes place early in the course of the disease. Measurements of 
larger brain volumes may thus be more precise and less susceptible to local changes. 
Quantitatively, most of pathology in HD is extrastriatal and relative contributions to disease 
manifestation by striatal atrophy are not known. Without effective treatment techniques it is 
not possible to validate whether change in MRI striatal volumes can serve as an effective 
surrogate endpoint (Aylard 2007) Also, basal ganglia are closely interconnected to many 
parts of human brain and their atrophy may be contributed to different clinical pathology.  
4.1 Brain volumes measurements 
Using a semi-automated MRI volumetric technique Rosas et al proved that numerous 
extrastriatal brain areas are atrophied (Rosas et al 2002). Using an automated MRI technique 
they further managed to demonstrate regional cortical thinning in early HD patients (Rosas 
et al 2003). In premanifest HD gene carriers selective thinning of cortical parts was found 
that correlated positively with changes in cognition measured by the cognitive part of 
UHDRS (Rosas et al 2005). Further analyses revealed a significant association between 
regional cortical thinning and total functional capacity which is the leading primary 
outcome measure in neuroprotection trials (Rosas et al 2008). Progression of HD was 
evaluated by a longitudinal follow up volumetric MRI analysis and efficient measurement 
of the volume changes was performed within 15 years from the estimated onset of the 
clinical disease (Aylard et al 2011). 
The boundary shift integral (BSI) is a semi- automated method by which changes in the 
brain volume can be calculated from registered 2-year interval scan pairs. Using BSI, Wild et 
al have demonstrated that whole-brain atrophy was significantly faster in early HD patients 
than in control subjects, and accelerated atrophy during the course of the disease was noted 
(Wild et al 2010). 
Voxel-Based Morphometry (VBM) is an automated technique for analysis of series of MRI 
scans. VBM identifies variably affected brain regions in different stages of HD (Kassubek et 
al 2004) Longitudinal studies using this technique are promising (Tabrizi et al 2011). 
The aforementioned MRI techniques are potentially useful in identifying the regions that 
may serve as biomarkers of disease progression in prevention trials. 
4.2 Functional MRI  
Functional MRI (fMRI) identifies subtle changes in regional blood flow during increased 
neuronal activity to identify brain regions active during performance of a specific task. Early 
abnormalities due to neuronal dysfunction can be detected. Neuronal dysfunction in early 
phase of the disease is potentially reversible which increases value of this technique. Thus, 
fMRI as a functional technique may reveal early functional pathology and may not require 
longitudinal measurements like morphometric methods. Several fMRI studies have 
demonstrated regional functional abnormalities in early HD (Georgiu-Karistanis et al 2007). 
A study conducted in presymptomatic HD gene carriers alterations in cortical functional 
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activity have been shown to correlate with the time of onset (Paulsen et al 2004) A study 
comparing data obtained from volumetric MRI and fMRI found that regions with altered 
activity were not those experiencing the most atrophy (Gavazzi et al 2007) While fMRI 
technique may represent a useful biomarker there are also weak points for its general use. 
Technical equipment is more demanding than conventional MRI and expertise of the 
technique is required.  
4.3 Molecular MRI techniques 
Diffusion tensor imaging (DTI) is an MRI technique developed from standard diffusion 
weight imaging (DWI) technique which applies the ability of water molecules to diffuse 
along axons and produces maps of white matter tracts. It can detect abnormalities in myelin 
which would appear normal on conventional MRI. In HD, the regions of decreased 
fractional isotropy (FI, measure of axonal organization) compared to controls were detected. 
Rosas et al found the regions that correlated to cognitive performance in presymptomatic 
HD gene carriers; more widespread lesions were detected in manifest HD (Rosas et al 2008). 
DTI shows promise to become a biomarker capable of detecting changes in HD earlier than 
other imaging techniques (Magnotta et al 2009) although not many studies have been 
performed and its potential remains to be tested.  
MR spectroscopy is capable of noninvasive quantification of the biochemical composition of 
brain tissue. Lower neuronal markers (N-acetylaspartate) levels were shown in 
presymptomatic and early HD, whereas glial cell markers (myo-inositol) were increased 
(Surrock et al 2010). Elevated lactate and reduced creatine levels were shown in the striatum of 
presymptomatic HD gene carriers and early HD patients (Reynolds et al 2005). The technique 
is capable of detecting biochemical changes in the central nervous system and promises to be 
helpful in a potential biomarker discovery; its utility, however, is limited by long scan times, 
small number of molecules it can accurately detect, and comparatively low sensitivity. 
5. Molecular biomarkers  
Various molecular biomarkers can also be obtained from peripheral blood, urine and 
cerebrospinal fluid (CSF). Ideally, biomarkers obtained from body fluids would be expected 
to reflect pathologic changes in CNS. Such a substance is normally not present in the blood, 
but in HD gene carriers/patients it leaks across blood-brain barrier and becomes detectable. 
However, mutant huntingtin is expressed ubiquitously over all body tissues, therefore 
molecular changes detected in body fluids may reflect peripheral processes promoted by 
mutant huntingtin. In this way, biomarkers obtained from CSF could reflect CNS pathology 
more precisely (Huang et al 2011).  
Candidate biomarkers obtained from body fluids can be divided in metabolic, endocrine, 
markers of oxidative stress, and markers obtained from signalling pathways.  
5.1 Metabolic biomarkers  
Due to ubiquitous expression of huntingtin in addition to neurological features peripheral 
deficits may be detected. HD–associated differences in metabolite levels in peripheral blood 
were detected by Underwood et al that identified a pro-catabolic pattern of metabolic 
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changes, present even in presymptomatic HD gene carriers (Underwood et al 2006). Another 
research group found decreasing levels of branched chain amino acids in presymptomatic 
HD gene carriers and clinically manifest HD patients in different stages of the disease 
compared to controls. The levels were found to correlate with CAG repeat length and UHDRS 
motor score (Mochel et al 2007). Uric acid, a known antioxidant agent that was found to be 
connected with the progression of Parkinson’s disease has been investigated as a putative 
biomarker/modifiable agent that could slow down HD progression (Auinger et al 2010). 
5.2 Endocrine biomarkers  
Several features of early HD like weight loss, depression, disturbed sleep cycle could be due 
to hypothalamic dysfunction. Undeniably, loss of hypothalamic cells has been found in HD 
patients (Petersen et al 2006). Endocrine disturbances that may track disease progression 
have been identified. Urinary cortisol levels increase progressively with the advancing 
disease in HD patients (Bjorquist et al 2006). Still other potential endocrine biomarkers are 
under investigation in clinically expresed HD (Hult et al 2010).  
Endocrine changes are of interest as potential biomarkers to track disease, yet endocrine 
features are susceptible to influence of drugs such as neuroleptics and antidepressants, and 
psychiatric pathology such as depression which may occur in early HD.  
5.3 Oxidative stress biomarkers  
Mitochondrial dysfunction has recently been shown in HD patients and presymptomatic 
HD gene carriers. (Saft et al 2005). Other markers of oxidative stress and metabolism are 
under investigation (Chen 2011). Mutant huntingtin and its cleavage products as the 
immediate cause of neuronal dysfunction and death in HD are being investigated as 
potential biomarkers (Moskovitch-Lopatin 2010).  
5.4 Signalling pathways biomarkers  
A significant decrease in brain-derived neurotrophic factor (BDNF), an agent that promotes 
survival of neurons was found in the serum of symptomatic HD patients (Ciammmola et al 
2007). Augmentation of neurotrophic gene products such as BDNF could present a potential 
therapeutic target in HD (Ross & Shoulson 2009). BDNF is an interesting potential biomarker 
of disease progression, however, it does not cross the blood-brain barrier. The balance of 
central and peripheral contributions to altered serum BDNF in HD requires further study. 
Abnormalities of the endocannabinoid system were observed in premanifest HD gene 
carriers as well as in manifest HD patients (Fernanadez-Ruiz et al 2009). Adenosine A2 
receptors were found to increased density and affinity in different stages of manifest HD as 
well as in presymptomatic HD gene carriers (Varani et al 2007). 
6. Autonomic nervous system function as a putative biomarker in HD 
Our research started with the study of autonomic nervous system function (ANS) in 
presymptomatic HD gene carriers and symptomatic HD patients. Based on a standardized 
clinical ANS questionnaire (Turkka 1987) a group of 33 patients was enrolled, among them 8 
presymptomatic HD gene carriers. Symptomatic patients were classified according to the 
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Shoulsoh and Fahn’s HD disability scale (Shoulson & Fahn 1979) to mildly affected group 
and moderately /severely affected which were evaluated together. Mostly, an increase in 
the ANS function , especially of the sympathetic part, was observed in presymptomatic HD 
gene carriers and mildly affected HD patients, and a decrease in the ANS function in 
moderately/severely affected patients was observed (Kobal et al 2004). Our further research 
was modified by observing a presymptomatic HD gene carrier in whom choreatic 
movements appeared after suffering from chronic subdural hematoma that compromised 
the cerebral cortex, but not the basal ganglia (Kobal et al 2007) (Fig. 1).  
 
Fig. 1. Computed tomography scan of the head in a patient with chorea discovering 
isodense bilateral chronic hematomas expanding over the entire right hemisphere and over 
the left parietooccipitotemporal cortex (a, b). Proton density weighted Magnetic resonance 
imaging 6 days after surgical evacuation and after reappearance of the initially regressed 
chorea showed no structural abnormality in the basal ganglia (c, d). 
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We hypothesized that early autonomic dysfunction could be due to imbalance in the central 
ANS centres and conducted further research in this direction. In the next study we enlarged 
the number of presymptomatic HD gene carriers and early manifest HD patients, which 
were clinically evaluated by UHDRS clinical scale. ANS tests to challenge higher-order ANS 
centres like mental stress and the cold pressor test were introduced. Attenuated response to 
simple mental arithmetic test was shown in a group of 14 presymptomatic HD gene carriers 
and 11 early symptomatic HD patients (Fig. 2). The response to late phase of cold pressor 
test in the same patients was exaggerated (Fig. 3). 
 
Fig. 2. (left): Arterial pressure and heart rate values during a simple mental arithmetic test. 
Values are expressed as percentage of resting arterial pressure and heart beat rates.  
* statistically significant differences between the groups (p<0.05). Fig. 2. (right): Heart rate 
and arterial pressure values during cold pressure test. Values are expressed as percentage of 
resting heart rate and arterial pressure values. * statistically significant differences between 
the groups (p<0.05). 
The results were in favour of highest-order cortical ANS centres hypofunction which, 
according to the concept of central autonomic network organization, could lead to 
hyperfunction of hypothalamus and lower order central autonomic centres (Kobal et al 2010, 
Melik et al-in print). Our findings were in line with the findings of a recent study on 
thalamic metabolism in preclinical HD. Thalamic metabolism was elevated at baseline, but 
fell to subnormal levels in the pre-HD subjects who developed symptoms (Feigin et al 2007). 
A recent survey found significantly more gastrointestinal, urinary cardiovascular and sexual 
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problems in group of HD patients. In premanifest HD group swallowing problems and 
light-headness on standing up were prominent (Aziz et al 2010) 
The ANS function could potentially represent a useful biomarker in HD however, further 
cross–sectional as well as longitudinal studies are needed. Drawbacks of these methods are 
that they are unspecific; they also may show variable intersubject response and are sensitive 
to use of drugs with anticholinergic effect such as neuroleptics which are commonly used in 
HD patients.  
7. “Omic” biomarkers for HD 
7.1 Use of “Omic” biomarkers in clinical practice 
Complete sequencing of the human genome has launched a new era of systems biology 
referred to as »omics«. The term refers to the comprehensive analysis of biological systems 
and a variety of omics subdisciplines are acknowledged. Through genomics new 
approaches to monitor diseases are becoming available. New technologies are capable of 
defining large sets of biomarkers systematically in biological samples (Bell 2004), and 
provide an analytical approach to investigation of all the products of the genome at 
messenger RNA or protein level at once. These methodologies are capable of generating 
data on multiple biomarkers that vary quantitatively very early in the disease, in response 
to disease onset, progression or therapeutic intervention and may provide sets of 
prognostic factors (Schadt et al 2003). The development of biomarkers for prognostic use 
in diseases with asymptomatic phases is particularly challenging and can be time-
consuming, as they must be validated and monitored in long-term clinical outcomes 
(Frank & Hargreaves 2003).  
Microarray analysis has significantly augmented the throughput of genomic studies and 
haemogenomic approach has been proposed; several examples of potential microarray-
based biomarkers in blood have already been described. Peripheral blood is an easily 
accessible tissue, and specific gene expression signatures have been shown to exist in a wide 
variety of diseases where no obvious clinical phenotype in blood is present, such as 
tuberous sclerosis, neurofibromatosis, Down syndrome, multiple sclerosis, etc (Tang et al 
2004, Bomprezzi et al 2003, Achiron et al 2004).  
Another two important goals of genomics and genetics in clinical practice, besides diagnosis 
and staging, are to improve therapeutic efficacy and reduce drug toxicity (Evans & Relling 
2004). The field of pharmacogenomics encircles the role of genes in an individual’s response 
to drugs and comprises a broad area of basic drug discovery research, the genetic basis of 
drug responses, pharmacodynamics, pharmacokinetics and metabolism. The implications 
for the development of new drugs and clinical patient management are huge. For example, 
in multiple sclerosis it has already been shown that differences in the gene expression 
profiles of treatment-responsive and treatment-non-responsive patients are present and 
detectable (Sturzebecher et al 2003). In cancer therapy, several studies have been published 
where expression signatures indicated the response to certain treatment (Glinsky et al 2005, 
Rosenwald et al 2002). In neurodegenerative diseases like HD, where no effective therapies 
are available and symptoms progression is relatively slow, biomarkers for therapy response 
monitoring are important. 
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7.2 Transcriptomic research in HD  
The research on HD has mainly been focused on the nervous system, only few studies have 
reported on muscle or other tissues. Our previous results show (Borovecki et al 2005) that 
expression changes of many genes were present and detectable in blood of HD patients when 
compared to healthy controls. Not only were these changes present in HD patients with 
clinical symptoms but disturbances in gene expression were detected in presymptomatic 
mutation carriers as well (Figure 3). The analysis of gene expression changes was performed 
on 2 different microarray platforms (Affymetrix, Amersham) in 12 symptomatic patients and 
10 healthy controls, as well as in 5 presymptomatic mutation carriers and 4 healthy controls. 
Ten times more probes were differentially expressed in symptomatic HD group than in 
presymptomatic HD group when compared to controls. Interestingly, Amersham detected up 
to 4 times more probes as differentially expressed in the symptomatic group than Affymetrix 
microarrays, whereas this was not the case in the presymptomatic group (Table 1). 
Based on this study, in which we have shown that gene expression changes in HD are 
detectable in blood of HD patients, research in the field of disease progression and novel 
therapy response in human HD may focus on this easily accessible tissue as well. Further 
work in the proposed direction is needed to provide clues to these implications. 
 SYMPTOMATIC GROUP PRESYMPTOMATIC GROUP 
p-value Affymetrix Amersham Affymetrix Amersham 
0.05 5267 12159 1369 939 
0.01 3133 9685 392 490 
0.005 2546 8678 223 314 
0.001 1646 6579 58 75 
0.0005 1366 5815 31 42 
0.0001 884 4191 3 8 
0.00005 740 3599 2 6 
Table 1. Numbers of differentially expressed probes between HD group and healthy 
controls. Numbers of changed probes are shown for each microarray platform separately 
with respect to different p-values. 
Only one study on gene expression changes in HD in human brain samples has been 
reported so far (Hodges et al 2006). The expression in three distinct brain regions from 
symptomatic HD patients was analyzed. We compared those with our expression results in 
blood of symptomatic HD patients on Affymetrix platform to compare expression changes 
in brain and blood (Table 2, Fig. 3). When using the same statistical measures (p<0.001) the 
greatest expression changes were observed in the caudate nucleus, followed by blood > BA4 
cortex > cerebellum. 30% of probe sets changed in blood were also significantly changed in 
caudate samples suggesting that HD specific changes might be detectable in blood. There 
was not a single probe set differentially expressed in all four tested tissues and 47 probe sets 
were significantly changed in blood, caudate and BA4 motor cortex, two of the more 
affected areas of brain in HD. These findings imply that similar cellular processes are 
disturbed in the caudate nucleus and blood cells, although there is no clinical phenotype in 
blood of HD patients. The latter may be due to the fact that unlike neurons, the life span of 
lymphocytes is short and the turn over rapid. 
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 Blood Caudate BA4 Cortex Cerebellum 
Number of changed probe sets 1646 5225 963 340 
Table 2. Numbers of probe sets differentially expressed in blood and three brain regions in 
symptomatic HD patients (p<0.001). 
 
Fig. 3. Numbers of over-lapping differentially expressed probe sets in blood, caudate and 
BA4 cortex (p<0.001). 
7.3 Age-at-onset prediction 
Since the gene expression changes were present already in presymptomatic stages, 
expression profiles might be used to refine the prediction of disease onset. There is a long 
time period before HD manifests itself through clinical symptoms. Due to available 
mutational testing, one can learn earlier about his/her gene mutation status. After the 
diagnosis, prediction of age at disease onset is most important information for mutation 
carriers and their relatives. Two ways to speculate about the age of onset have been 
accepted so far, both quite insensitive – number of CAG repeats and polymorphisms of 
modifier genes. Age of onset may presently only be given in a rather wide range – for 
example a mutation carrier with 42 CAG repeats will most probably develop symptoms 
between 35-57 years of age. Clearly, this is of no use to someone to plan the future. Brain-
imaging studies have been trying to add some sensitivity to the prediction of disease onset. 
Study of basal ganglia volume showed that atrophy of basal ganglia occured gradually, 
beginning years before symptoms onset (Aylard 2007). Mutation carriers who were close to 
the onset of HD as predicted by CAG repeat numbers had smaller volumes of basal ganglia 
than subjects far from onset for all structures except the caudate nucleus. Mutation carriers 
who were far from the onset had smaller basal ganglia volumes than healthy controls for all 
structures except the globus pallidus. A functional MR imaging (fMRI) study showed 
differences in the groups of mutation carriers far or close to the predicted age of onset when 
compared to healthy controls (Paulsen et al 2004). The group close to the onset had 
significantly less activation in subcortical regions than control subjects and the group far 
from the predicted onset had an intermediate degree of activation. Despite the mentioned 
findings there have not been any definite measurements or protocols for determining the 
age of onset proposed so far. 
www.intechopen.com
 
Huntington’s Disease — Core Concepts and Current Advances 
 
112 
Our results suggest that gene expression in blood of HD mutation carriers is disturbed long 
before the onset of symptoms (some of tested mutation carriers were as young as 20 years 
with CAG repeat lengths of 41, suggesting the start of the disease between 40-50 years of 
age). These results imply that gene expression changes in blood might potentially be used 
not only to monitor the disease progression but to help predict the age of disease onset as 
well. Also, expression changes correlated with the disease progression in the symptomatic 
stages of HD, and they might be valuable in determining the progression of specific 
symptoms in the advanced stages. 
7.4 Potential biomarkers of disease progression 
Whole genome transcriptome analysis might define also biomarkers for disease progression. 
Using whole genome gene expression data from our study (Borovecki et al 2005) we have 
performed additional analysis to select a potential biomarker set – set of genes to be useful 
as a biomarker and test their expression with another independent method, quantitative 
RTPCR (QRT-PCR). To narrow down the list of differentially expressed genes, additional 
criteria for selecting genes of interest were implemented. We have selected top 12 candidate 
genes that had the best reproducibility of expression changes when tested with QRT-PCR in 
presymptomatic/symptomatic HD patients and healthy controls.  
To make a study more stringent we validated the 12 gene set on an independent set of HD 
samples and controls (Fig. 4). Expression of individual genes increased with disease 
progression from the presymptomatic to advanced symptomatic stage, but the differences 
did not reach statistical significance. While only 6 genes, ANXA, MARCH7, CAPZA1, 
HIF1A, TAF7 and YPEL5, were significantly upregulated in the presymptomatic (P) group 
(p<0.05), 10 genes were significantly upregulated in the symptomatic (S) group (p<0.05) 
(PCNP and SF3B1 were not significant) and 11 genes were significantly upregulated in the 
late symptomatic (LS) group (p<0.05) (SF3B1 was not significant). 
This study provided confirmatory evidence of significant gene expression changes in blood 
of HD patients published by Borovecki et al. Expression of the 12 genes appeared higher in 
the advanced symptomatic group of patients compared to the presymptomatic group, but 
these stage-dependent differences in expression did not reach statistical significance. In 
order to investigate predictive performance of the gene set, we examined logistic regression 
machine learning algorithm on our dataset. Proposed classifier reached overall positive 
predictive value of 78% with 82% sensitivity and 53% specificity for HD with respect to 
healthy control. In addition, the potential of gene set to discriminate between 
presymptomatic and symptomatic patients was evaluated using the logistic regression 
algorithm. The results showed overall positive predictive value of 85% with relatively high 
sensitivity (83%), but with low specificity (50%). A possible explanation for low specificity 
may be the unequal distribution of cases in our dataset (14 presymptomatic and 47 
symptomatic cases) and small set of training cases (Lovrecic et al 2009).  
While high specificity and sensitivity are generally desirable for diagnostic biomarkers, 
these parameters are not essential in diseases such as HD where the diagnosis is already 
known and the intended use of biomarkers is to primarily monitor disease progression. As a 
potential marker of disease progression, the 12-gene set showed promising overall positive 
predictive value and sensitivity (85% and 83%, respectively), but with relatively low 
specificity (50%). Nevertheless, our results suggest that the 12-gene set may be of better 
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clinical value compared to individual genes as a marker of disease progression in HD.  
Moreover, we hypothesize that including more altered genes in the gene set may further 
enhance its clinical applicability. 
 
Fig. 4. Expression fold changes of 12 genes in different stages of HD. 
The upregulation of expression of the 12 previously selected genes (8) was validated in the 
new cohort of HD patients. Bars represent fold increase in mRNAs in HD patients relative to 
healthy controls. Interval lines represent the (average fold change) x (2SEM-1). P-
presymptomatic HD mutation carriers, S-symptomatic patients, LS-late symptomatic 
patients: ANXA-annexin A1; MARCH7-membrane-associated ring finger 7; CAPZA1-
capping protein muscle Z-line, alpha 1; HIF1A-hypoxia-inducible factor 1, alpha subunit; 
SUZ12-suppressor of zeste 12 homolog; P2RY5-purinergic receptor P2Y, G-protein coupled, 
5; PCNP-PEST proteolytic signal containing nuclear protein; ROCK1-Rho-associated, coiled-
coil containing protein kinase 1; SF3B1-splicing factor 3b, subunit 1; SP3-Sp3 transcription 
factor; TAF7-TAF7 RNA polymerase II, TATA box binding protein (TBP)-associated factor; 
YPEL5-Yippee-like 5. 
In addition, another study of global gene expression in lymphoblastic cell lines from HD 
patients failed to identify any significant changes in gene expression (Runne et al 2007) that 
were observed previously (Borovecki et al 2005). It is therefore evident that multiple 
independent validation studies will be required to evaluate potential clinical applicability of 
a putative biomarker. While development of novel hemogenomic approaches to non-
invasively monitor disease progression showed promise, it remains unclear whether the 
observed changes in blood gene expression will be sufficiently robust to serve as biomarkers 
of disease. A combination of genomic, metabolomic and proteomic approaches may be 
required, in combination with neuroimaging, to successfully identify biomarkers of disease 
progression in HD and probably other neurodegenerative diseases.  
7.5 Elucidation of pathophysiological processes in HD 
Analysis of whole genome transcriptome might also give us insights into the disturbed 
pathways and processes involved in disease onset and progression. Although multiple 
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pathological mechanisms by which mutant htt causes neuronal dysfunction have been 
proposed and studied in detail (Harjes & Wanker 2003), the exact molecular mechanisms 
how mutant htt induces cell death are not understood.  
Using whole genome gene expression data from our study (Borovecki et al 2005) we have 
performed additional bioinformatic analysis of microarray data with freely available Onto-
Tools (Draghici et al 2003) and Gene set enrichment analysis (GSEA) (Subramanian et al 
2005) software. Three separate comparisons were done: 1) all HD samples compared to 
healthy control samples (HDvsC); 2) symptomatic HD samples compared to healthy control 
samples (SvsC); 3) presymptomatic HD samples compared to healthy control samples 
(PvsC). When looking for enriched gene set with GSEA, additional comparison was done - 
symptomatic HD samples compared to presymptomatic HD samples (SvsP). Onto- Express 
was used to more thoroughly characterize the sets of functionally related differentially 
expressed genes (Draghici et al 2003, Khatri et al 2002). The tool classified genes according to 
two Gene-Ontology (GO) categories: biological process and molecular function (Fig. 5). 
  
Fig. 5. Common molecular function categories changed in presymptomatic (Presym) HD 
mutation carriers and symptomatic (Sym) HD patients. 
Molecular function category Category rank* Genes in category (%) 
Structural constituent of ribosome 5 2.9
Unfolded protein binding 6 2.6
GTPase activity 7 2.3
Protein transporter activity 9 1.9
Protein heterodimerization activity 10 1.6
RNA polymerase II transcription factor activity 12 1.3
Hydrogen-transporting ATPase activity 13 1.3
Translation elongation factor activity 14 1
Helicase activity 15 1
Ubiquitin conjugating enzyme activity 16 1
* Category rank from PvsC comparison. 
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Using Onto-tools we may propose that two novel mechanisms are disturbed in early stages 
of HD. Molecular function categories “metal ion binding” and “helicase activity” have been 
shown to be disrupted already in presymptomatic HD mutation carriers (Fig. 5, Table 3). 
Another interesting finding was that many more molecular function and biological process 
categories were disturbed at the gene expression level in presymptomatic than in 
symptomatic group (Table 3).  
Using another method, Gene set enrichment analysis (GSEA) two additional mechanisms in 
terms of gene sets were significantly upregulated in the presymptomatic group - lipid 
metabolism with adipocyte function (Nadler et al 2000) and gene set linked to expression 
changes in major depressive disorder (Aston et al 2005). Also, our results have confirmed 
most of the previously described potential pathogenetic mechanisms to be disturbed at gene 
expression level using two completely different approaches.  
Many hypotheses on HD pathogenesis have been investigated, but none has been able to 
decipher the basis of what goes wrong first. Since HD primarily affects the brain, majority of 
the research on the pathogenesis has been done on neuronal cells or tissue. We used a 
different approach in two aspects – we included presymptomatic mutation carriers that 
gave us an insight into the early changes in HD, and our analyses were done on blood cells 
which appear not to be affected in HD. Possibly, if their life span were longer, as is the case 
with neuronal cells, blood cells would also become affected. One study reported that 
lymphoblasts isolated from HD patients showed increased stress-induced apoptotic cell 
death, suggesting their abnormal function, but no apparent clinical phenotype was found 
present (Sawa et al 1999). These are more reasons to believe that the changes present in 
blood cells are early changes characteristic of HD. Moreover, the analysis of gene expression 
changes in presymptomatic mutation carriers separately might lead to explanation of some 
primarily disturbed mechanisms specific for HD. 
Metal ion binding category was disturbed already in presymptomatic disease stage and only 
scarce data are currently available on metal ions in neurodegenerative diseases affecting 
basal ganglia (Dexter et al 1991, Moos & Morgan 2004). The results of previous studies have 
suggested that metal ions might contribute to neurodegenerative process. More studies are 
needed to elucidate the importance of metal ions in HD, but our results suggest that related 
mechanisms are disturbed already in presymptomatic disease stages. Interestingly, the 
analysis of molecular function and biological process GO categories have shown that many 
more categories are changed specifically in presymptomatic HD stages implying that many 
processes are active and changed in comparison to healthy controls before the onset of 
clinical symptoms. Since they are not present in symptomatic stages of HD they might 
exhibit the measures that cells are undertaking to counteract to mutation driven 
disturbances and efforts to execute normal processes appropriately. 
In addition, expression results from our study showed that gene set consisting of genes 
controlling lipid metabolism and signal transduction (Nadler et al 2000) was specifically 
changed in the group of presmyptomatic HD mutation carriers. Disturbed lipid metabolism 
and an adipocyte function have been previously reported in R6/2 mice, where a defect in fat 
breakdown by adipocytes was suggested (Fain et al 2001). No results on human samples 
have been available so far. Our results suggest that this might be one of the mechanisms 
disturbed early in the human HD pathogenesis. The second gene set significantly enriched 
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in presymptomatic group was previously defined in a study of expression changes in brain 
in major depressive disorder (Aston et al 2005) where a disruption in the expression of 
genes involved in neurodevelopment, signal transduction, synaptic function and cell 
communication was shown. Psychiatric symptoms usually precede motor impairment in 
HD for a few years and depression is one of them. Perhaps this might be the explanation for 
discovered enrichment of this gene set specifically in the presymptomatic HD group. 
8. Conclusion 
We conclude that identification of easily obtainable, reliable and robust biomarkers of 
Huntington’s Disease progression will be important for development and evaluation of 
future therapies (Weir DW et al 2011). Specific pathogenic mechanisms can be readily 
proven by clinical, neuroimaging, and/or biochemical biomarkers. Peripheral blood due to 
its easy accessibility might be a representative tissue for genomic HD specific changes 
investigation and a potential tissue of choice for monitoring the course of the disease. 
However, without the effective treatment techniques it is not yet possible to validate which 
biomarker can serve as an effective surrogate endpoint for the disease process modification.  
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